Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Morning Bell 26 July

Grady Wulff
July 26, 2023

Morning Bell 25 July

Sophia Mavridis
July 25, 2023

Morning Bell 24 July

Grady Wulff
July 24, 2023

Weekly Wrap 21 July

Grady Wulff
July 21, 2023

Morning Bell 21 July

Sophia Mavridis
July 21, 2023

Morning Bell 20 July

Sophia Mavridis
July 20, 2023

Morning Bell 19 July

Grady Wulff
July 19, 2023

Morning Bell 18 July

Grady Wulff
July 18, 2023

Morning Bell 17 July

Grady Wulff
July 17, 2023

Weekly Wrap 14 July

Grady Wulff
July 14, 2023

Morning Bell 14 July

Sophia Mavridis
July 14, 2023